Drugs /

zanubrutinib

Back to Drugs List

Overview

Trade Name(s):
Brukinsa
NCI Definition [1]:
An orally available inhibitor of Bruton tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the TEC family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.

Clinical Trials

View Clinical Trials for zanubrutinib

Zanubrutinib has been investigated in 13 clinical trials, of which 11 are open and 2 are closed. Of the trials investigating zanubrutinib, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 3 are phase 3 (3 open).

MS4A1 Expression, TP53 Loss, and TP53 Mutation are the most frequent biomarker inclusion criteria for zanubrutinib clinical trials.

Mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma are the most common diseases being investigated in zanubrutinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Zanubrutinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Zanubrutinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating zanubrutinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
btk inhibitor bgb-3111, bgb-3111, btk-inhb, brukinsa
Drug Target(s) [2]:
BTK
NCIT ID [1]:
C141428

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.